| [1] ALLEGRA A,ALONCI A,CAMPO S,et al. Circulating microRNAs:new biomarkers in diagnosis,prognosis and treatment of cancer (review)[J]. Int J Oncol,2012,41(6):1897-1912.[2] LEWIS B P,BURGE C B,BARTEL D P. Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets[J]. Cell,2005,120(1):15-20.[3] FRIEDMAN R C,FARH K K,BURGE C B,et al. Most mammalian mRNAs are conserved targets of microRNAs[J]. Genome Res,2009,19(1):92-105.[4] MA R,JIANG T,KANG X. Circulating microRNAs in cancer:origin,function and application[J]. J Exp Clin Cancer Res,2012,31:38.[5] LAWRIE C H,GAL S,DUNLOP H M,et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J]. Br J Haematol,2008,141(5):672-675.[6] THERY C,ZITVOGEL L,AMIGORENA S. Exosomes:composition,biogenesis and function[J]. Nat Rev Immunol,2002,2(8):569-579.[7] COCUCCI E,RACCHETTI G,MELDOLESI J. Shedding microvesicles:artefacts no more[J]. Trends Cell Biol,2009,19(2):43-51.[8] TOMIMARU Y,EGUCHI H,NAGANO H,et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J]. J Hepatol,2012,56(1):167-175.[9] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.[10] 周新,府伟灵. 临床生物化学与检验[M]. 人民卫生出版社,2007:405-409.[11] KOTB S,MOSHARAFA A,ESSAWI M,et al. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer[J]. Tumour Biol,2014,35(12):12613-12617.[12] ZHANG H L,YANG L F,ZHU Y,et al. Serum miRNA-21:elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy[J]. Prostate,2011,71(3):326-331.[13] 吕桂帅,陈磊,王红阳. 我国肝癌研究现状与前景[J]. 中国生命科学通报,2015(3):237-248.[14] WALEED A,HISHAM A. Diagnostic potential of circulating microRNA-21 in hepatocellular carcinoma[J]. Int J Sci Technol Res,2015,4(9):429-433.[15] 魏志,孙自勤,董伟,等. 血清癌胚抗原及大便隐血试验诊断大肠癌价值[J]. 中华实用诊断与治疗杂志,2010(11):1075-1076.[16] KANAAN Z,RAI S N,EICHENBERGER M R,et al. Plasma miR-21:a potential diagnostic marker of colorectal cancer[J]. Ann Surg,2012,256(3):544-551.[17] BASATI G,EMAMI R A,ABDI S,et al. Elevated level of microRNA-21 in the serum of patients with colorectal cancer[J]. Med Oncol,2014,31(10):205.[18] MENENDEZ P,Padilla D,VILLAREJO P,et al. Prognostic implications of serum microRNA-21 in colorectal cancer [J]. J Surg Oncol,2013,108(6):369-373.[19] 赵建国,叶万立,吴东平,等. 替吉奥联合奥沙利铂治疗晚期结肠癌前后血浆miR-21表达水平变化及其临床意义[J]. 中国临床药理学与治疗学,2016(3):318-321.[20] WU J,LI G,WANG Z,et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer[J]. Dis Markers,2015:435656.[21] GAO J,ZHANG Q,XU J,et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA[J]. Chin J Cancer Res,2013,25(6):743-748.[22] TORAIHE A,MOHAMMED E A,FARRAG S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in egyptian breast cancer patients[J]. Mol Diagn Ther,2015,19(3):179-190.[23] WITWER K W. Circulating microRNA biomarker studies:pitfalls and potential solutions[J]. Clin Chem,2015,61(1):56-63.[24] MONTAGNANA M,BENATI M,DANESE E,et al. Plasma expression levels of circulating miR-21 are not useful for diagnosing and monitoring colorectal cancer[J]. Clin Lab,2016,62(5):967-970. |
